For large companies, it's not just about the money. There's more they can offer startups. Getty Images

As times and technologies change, large companies need to be able to adopt innovative techniques now more than ever. For some companies, that means making a strategic hire, investing in startups, or making acquisitions.

Three panelists with experience in corporate ventures took the stage at the inaugural HX Capital Summit to discuss their best advice for startups looking for investment from large companies.

The panel consisted of Roy Johnston, partner at The League of Worthwhile Ventures; Tom Luby, head of Jlabs; Andrea Course, venture principal at Schlumberger Technical Investments; and moderator Rashad Kurbanov, CEO of Houston-based iownit capital and markets.

The topic of conversation was how corporations work with startups. For Schlumberger, Course says, it's less about acquiring companies and more about investing in technologies those startups are working on.

"When Schlumberger does invest, we like to have a pilot and invest in properties we can grow," Course says. "Our intent is not to go out and buy a startup company, but to grow the technology and then become customers."

Schlumberger has a lot to offer a budding company, namely resources, infrastructure, assets, and a global footprint, Course says.

Previous to his position at The League, Johnston was the director in the venture capital arm of Waste Management, Inc. He says he saw a similar resources-based investment strategy.

"Waste Management might have been more hesitant to write a check, but they were very generous with their assets," Johnston says.

The company could make connections for the startups and provide other support for entrepreneurs in the early stages of starting a company. However, when it came to monetary investments, Johnston says, it was a different story.

"Where I think Waste Management comes in is later on — more of an acquirer than an investor," Johnston says.

When it comes to the types of startups big companies are looking to work with, industry isn't a big issue. Johnson & Johnson, for instance, has an open mind, Luby says.

"It's not an easy fit to say a specific area where J&J fits — if you look at the profile of things we do, we have a no-strings-attached incubation hub next door," he says.

Schlumberger similarly looks outward to spark innovation inward — mostly, Course says, because it's so challenging to think outside the box when you're working everyday inside the box.

"We mostly invest in companies outside of oil and gas, but that we see the potential of bringing used in our industry," Course says.

Houston, has a surplus of diversity — both industry and population, Johnston says. This will be a huge asset of the city, he says, since Houston is on the edge of another revolution for digitization.

"The businesses that are going to be built are going to need people who have a diverse understanding of problems," Johnston says. "That's where I think Houston's diversity is an enormous benefit to us."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

This Houston suburb named one of 10 newest boomtowns in U.S.

Booming 'Burb

What do you get when you combine a city's surge in population, housing growth, and economy? For the Houston suburb of Conroe, it adds up to being America's No. 9 newest boomtown, according to a new survey from SmartAsset.

The personal finance website's just-released report analyzed more than 400 U.S. cities with populations of 65,000 or more to identify places experiencing rapid growth based on five-year changes in economic output, housing units, and labor force size.

Texas is home to the second-highest concentration of new boomtowns in America with 18 out of 75 located in the Lone Star State. Only Florida ranks higher than Texas by just one.

However, Texas nearly locked out the top five most bustling boomtowns in America. Austin suburb Georgetown topped the list, and its Central Texas neighbors New Braunfels (No. 2) and Leander (No. 4) ranked close behind. Dallas-Fort Worth mid-city Lewisville claimed the No. 5 spot. Lehi, Utah ranked in third place.

Conroe has soared in popularity as one of America's most sought-after suburbs over the last several years, boosted by its renter-friendliness and its livability among the millennial generation.

Conroe has seen a 37 percent increase in housing units from 2019 to 2024, with its labor force growing by 33 percent during that time. SmartAsset also determined that Montgomery County's economic output grew at compound annual rates of 4.9 percent.

The report says population booms and "expanding business activity" can create "visible momentum" for an up-and-coming city, but these fast changes can alter a city in ways residents may not expect.

"In recent years, some American cities stand out for attracting people, investment and development at a pace that sets them apart," the report said. "Boomtown status does not mean growth benefits everyone equally, but it does reflect a city’s expanding economic capacity and the new opportunities that come with it."

America's top 10 new boomtowns are:

  • No. 1 – Georgetown
  • No. 2 – New Braunfels
  • No. 3 – Lehi, Utah
  • No. 4 – Leander
  • No. 5 – Lewisville
  • No. 6 – Palm Coast, Florida
  • No. 7 – Nampa, Idaho
  • No. 8 – McKinney
  • No. 9 – Conroe
  • No. 10 – Frisco
---

This article originally appeared on CultureMap.com.

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.